Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 1, 2013, Pages 67-76

  Vandyke, Kate ^a   Fitter, Stephen ^a   Drew, Jenny ^a   Fukumoto, Seiji ^b   Schultz, Christopher G ^c   Sims, Natalie A ^d   Yeung, David T ^e   Hughes, Timothy P ^a   Zannettino, Andrew C W ^a  

^a CENTRE FOR CANCER BIOLOGY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; IMATINIB; PARATHYROID HORMONE; PHOSPHATE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MASS; BONE REMODELING; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CELL COUNT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE MARKER; DRUG EFFICACY; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FEMALE; FEMUR NECK; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MICRO-COMPUTED TOMOGRAPHY; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; PARATHYROID HORMONE BLOOD LEVEL; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRABECULAR BONE;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY; BONE REMODELING; FEMALE; FEMUR NECK; FOREARM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; ORGAN SPECIFICITY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84872057752     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2426     Document Type: Article

References (63)

1. Okuda K, Weisberg E, Gilliland DG, Griffin JD 2001 ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448
2. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB 2000 Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145
3. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, Lyons AB 2005 Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105:3127-3132
4. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G 2008 Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 599:44-53
5. Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, Supuran CT 2009 The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian α-carbonic anhydrase isoforms. Bioorg Med Chem Lett 19:4102-4106
6. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic- phase chronic myeloid leukemia. N Engl J Med 348:994-1004
7. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417
8. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM 2008 Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood 111:1039-1043
9. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC 2008 Long-term imatinib therapy promotes bone formation inCMLpatients. Blood 111:2538-2547
10. Jönsson S, Olsson B, Ohlsson C, Lorentzon M, Mellström D, Wadenvik H 2008 Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 93:1101-1103
11. O'Sullivan S, Horne A, Wattie D, Porteous F, Callon K, Gamble G, Ebeling P, Browett P, Grey A 2009 Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 94:1131-1136
12. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC 2010 Dysregulation of bone remodeling by imatinib mesylate. Blood 115:766-774
13. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, Zannettino ACW 2006 Imatinib as a potential antiresorptive therapy for bone disease. Blood 107:4334-4337
14. Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H 2006 Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 24:274-282
15. El Hajj Dib I, Gallet M, Mentaverri R, Sévenet N, Brazier M, Kamel S 2006 Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 551:27-33
16. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP 2006 Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006-2013
17. Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, Boxberger S, Bornhäuser M 2007 Inhibition of platelet-derived growth factor receptor β by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif 40:355-366
18. O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, Watson M, Cornish J, Browett P, Grey A 2007 Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 22:1679-1689
19. Wihlidal P, Karlic H, Pfeilstöcker M, Klaushofer K, Varga F 2008 Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines. Leuk Res 32:437-443
20. Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A, Conticello C, Palumbo GA, Di Raimondo F 2009 Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 37:461-468
21. Jönsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T 2012 Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. J Bone Miner Metab 30:119-123
22. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino ACW 2010 Plasma adiponectin levels are markedly elevated in imatinib- treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95:3763-3767
23. Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, Sims NA, Zannettino AC 2010 The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res 25:1759-1770
24. Nordin BE, Morris HA, Need AG, Horowitz M, Robertson WG 1990 Relationship between plasma calcium fractions, other bone-related variables, and serum follicle-stimulating hormone levels in premenopausal, perimenopausal, and postmenopausal women. Am J Obstet Gynecol 163:140-145
25. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960
26. Osorio S, Noblejas AG, Durán A, Steegmann JL 2007 Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 82:394-395
27. Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gambacorti-Passerini C 2008 Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica 93:317-318
28. Mahon F-X, Huguet F, Etienne G, Réa D, Cayuela J-M, Marit G, Gardembas M, Reiffers J, Rousselot P 2006 Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission: an update follow up. Blood 108:2154
29. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M, Mahon FX 2007 Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58-60
30. Ross DM, Hughes TP 2008Howcomplete is "complete" molecular response in imatinib-treated chronic myeloid leukemia? Leuk Lymphoma 49:1230-1231
31. Ross DM, Grigg A, Schwarer A, Arthur C, Loftus K, Mills AK, Filshie R, Columbus R, Reynolds J, Seymour JF, Branford S, Hughes T 2008 The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early. Blood 112:1102
32. Mahon F, Rea D, Guilhot F, Legros L, Guilhot J, Aton E, Dulucq S, Reiffers J, Rousselot P 2009 Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: interim analysis of the STIM trial. J Clin Oncol 27:7084
33. Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM 1985 The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37:594-597
34. Ikeda S, Morishita Y, Tsutsumi H, Ito M, Shiraishi A, Arita S, Akahoshi S, Narusawa K, Nakamura T 2003 Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoid-treated growing minipigs. Bone 33:779-787
35. Teo JCM, Si-Hoe KM, Keh JEL, Teoh SH 2007 Correlation of cancellous bone microarchitectural parameters from microCT to CT number and bone mechanical properties. Mat Sci Eng C-Bio S 27:333-339
36. Frydecka I, Bieniek J, BrodzkaW 1984 Osteolytic lesion in chronic myelogenous leukaemia. Folia Haematol Int Mag Klin Morphol Blutforsch 111:610-613
37. Thiele J, Hoeppner B, Wienhold S, Schneider G, Fischer R, Zankovich R1989 Osteoclasts and bone remodeling in chronic myeloproliferative disorders. A histochemical and morphometric study on trephine biopsies in 165 patients. Pathol Res Pract 184:591-599
38. Kwong YL, Ng IO, Leung SY 1990 Osteolytic skeletal lesions in chronic myeloid leukemia. Pathology 22:124-125
39. Maloisel F, Favre G, Mahmal L, Zamfir A, Andrès E 2005 Isolated lytic bone lesion as extramedullary disease in chronic myelogenous leukemia: a report of three new cases. Eur J Intern Med 16:288-290
40. Schabel SI, Tyminski L, Holland RD, Rittenberg GM 1980 The skeletal manifestations of chronic myelogenous leukemia. Skeletal Radiol 5:145-149
41. Nadal E, Cervantes F, Rosiñol L, Talarn C, Montserrat E 2001 Hypercalcemia as the presenting feature of t-cell lymphoid blast crisis of Ph-positive chronic myeloid leukemia. Leuk Lymphoma 41:203-206
42. Grey A, O'Sullivan S, Reid IR, Browett P 2006 Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 355:2494-2495
43. Ste-Marie LG, Sod E, Johnson T, Chines A 2004 Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75:469-476
44. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW,Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A 2000 Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 85:720-726
45. Cheer SM, Noble S 2001 Zoledronic acid. Drugs 61:799-805; discussion 806
46. Peter R, Mishra V, Fraser WD 2004 Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 328:335-336
47. Tanvetyanon T, Stiff PJ 2006 Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897-907
48. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480
49. Eriksen EF, Melsen F, Sod E, Barton I, Chines A 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620-625
50. Parisien MV, McMahon D, Pushparaj N, Dempster DW 1988 Trabecular architecture in iliac crest bone biopsies: infra-individual variability in structural parameters and changes with age. Bone 9:289-295
51. Bonucci E, Ballanti P, Della Rocca C, Milani S, Lo Cascio V, Imbimbo B 1990 Technical variability of bone histomorphometric measurements. Bone Miner 11:177-186
52. Chappard C, Marchadier A, Benhamou L 2008 Interindividual and intraspecimen variability of 3-D bone microarchitectural parameters in iliac crest biopsies imaged by conventional micro-computed tomography. J Bone Miner Metab 26:506-513
53. Cummings SR, Melton LJ 2002 Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767
54. Lanyon LE 1984 Functional strain as a determinant for bone remodeling. Calcif Tissue Int 36(Suppl 1):S56-S61
55. Rubin CT, Lanyon LE 1985 Regulation of bone mass by mechanical strain magnitude. Calcif Tissue Int 37:411-417
56. Carter DR 1984 Mechanical loading histories and cortical bone remodeling. Calcif Tissue Int 36(Suppl 1):S19-S24
57. Jowsey J 1974 Bone histology and hyperparathyroidism. Clin Endocrinol Metab 3:267-284
58. Christiansen P, Steiniche T, Brockstedt H, Mosekilde L, Hessov I, Melsen F 1993 Primary hyperparathyroidism: iliac crest cortical thickness, structure, and remodeling evaluated by histomorphometric methods. Bone 14:755-762
59. Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R 1996 Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 81:3487-3491
60. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE 2001 Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054
61. Locklin RM, Khosla S, Turner RT, Riggs BL 2003 Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 89:180-190
62. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA 2004 PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19:235-244
63. Mosekilde L 2008 Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 69:1-19